Low-dose Colchicine in Patients With Type 2 Diabetes Mellitus and Microalbuminuria
Status:
Active, not recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
1. The primary objective of this study was： in patients with type 2 diabetes and
microalbuminuria who have been receiving stable treatment of angiotensin-converting
enzyme inhibitor/angiotensin II receptor blocker (ACEI/ARB) for at least 3 months,
whether low-dose colchicine slows the progression of microvascular complications.
2. The secondary objective of this study was： (1) whether low-dose colchicine could reduce
Urinary Albumin To Creatinine Ratio (UACR), or improve eGFR in patients with type 2
diabetes and microalbuminuria; (2) whether low-dose colchicine decreases carotid
intima-media thickness(IMT) in patients with type 2 diabetes and microalbuminuria; (3)
whether low-dose colchicine reduces the risk of cardiovascular events or mortality in
patients with type 2 diabetes and microalbuminuria.